SECTIONS
SUBSCRIBE
Managed Care

Search form

  • News
  • Politics & policy
  • Drug management
  • Payers
  • Providers
  • Current Issue
  • More
    • Past issues
    • Value-Based Care
    • Profiles
    • Conversations
    • Tomorrow's Medicine
    • Original research
    • Pharm D Corner
    • Viewpoints
    • Legislation & regulation
    • Contact Us

Most Popular

Guidelines Describe Appropriate Care for People Living With HIV and Cancer

The National Comprehensive Cancer Network (NCCN) has released new NCCN Clinical Practice Guidelines in Oncology intended to help make sure people living with human immunodeficiency virus (HIV) infection who are diagnosed with cancer receive safe, necessary treatment. In 2010, an estimated 7,760 people…
Read more

FDA Approves New, Larger Toujeo Pen

The FDA has approved Toujeo (insulin glargine 300 units/mL, Sanofi) Max SoloStar, the highest capacity long-acting insulin pen that will be available on the market. The new pen holds 900 units of Toujeo, more than any other long-acting insulin pen in the U.S., and provides up to 160 units/mL of Toujeo…
Read more

Blincyto Indication Expanded to Include Certain Leukemia Patients at Increased Risk for Relapse

The FDA has granted accelerated approval to blinatumomab (Blincyto, Amgen) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). MRD refers to the presence of cancer cells below a level that can be seen…
Read more

Phase 3 Failure Scuttles Cystic Fibrosis Drug

Disappointing results in the phase 3 RESULT trial have led Anthera Pharmaceuticals, Inc., to discontinue development of its drug candidate Sollpura for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis. Sollpura failed to meet the trial’s primary endpoint: noninferiority in…
Read more

MS Drug Zinbryta To Be Withdrawn From the Market

The multiple sclerosis medication daclizumab (Zinbryta, Biogen/AbbVie) is being withdrawn from the market voluntarily following reports that it has been associated with inflammatory encephalitis and meningoencephalitis. The two companies said that “characterizing the complex and evolving benefit/risk…
Read more

Tasigna Gets FDA Nod to Treat Children With Rare Form of Leukemia

The FDA has expanded the indication for nilotinib (Tasigna, Novartis) to include treatment of first- and second-line pediatric patients 1 year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). In the United States, nilotinib is now indicated…
Read more

WalletHub Healthy Cities List Favors California, Pans Texas

Looking for healthy folks? Take a trip to San Francisco or Seattle, WalletHub suggests. But if your journey takes you through Brownsville or Laredo, Texas, don’t bother stopping. With health care costs rising and U.S. life expectancy declining for the second year in a row, the personal-finance website…
Read more

House Passes Right-to-Try Legislation on Second Attempt

The second time proved to be the charm for the U.S. House of Representatives to pass right-to-try legislation that would provide terminally ill patients access to experimental drugs without the approval of the FDA, according to a BioSpace article. The House approved a second bill with a 267–149 vote…
Read more

Invokana Reduces Cardiac Problems in Diabetes Patients

Canagliflozin (Invokana, Janssen Pharmaceutical) significantly reduced the risk of cardiovascular death or hospitalization for heart failure in patients with type-2 diabetes at high cardiovascular risk in an exploratory analysis from the CANVAS clinical program, according to a presentation at the American…
Read more

Stop Letting Eggs Scramble Flu Vaccines, GlobalData Says

The alarmingly high number of pediatric deaths so far during the 2017–2018 flu season reinforce the need to shift away from the traditional chicken-egg-based approach to mass production of commercial influenza vaccines, according to consultant GlobalData. The egg-based vaccines commonly induce a suboptimal…
Read more

Amazon, Berkshire, JPM Form Health Care Company to Cut Costs

Amazon.com, Inc., Berkshire Hathaway, and JPMorgan Chase & Co. will form a health care company aimed at cutting costs for their U.S. employees, the three partners have announced. Reuters reports that the news sent shares in the broad health care sector sharply lower. The independent company will be…
Read more

Report: Opioid Manufacturers Gave Millions to Advocacy Groups

A new report from Senator Claire McCaskill (D-Missouri) found that five opioid manufacturers paid nearly $9 million to 14 outside groups between 2012 and 2017, alleging that the advocacy groups often “amplified messages favorable to increased opioid use.” The groups—many of which work on chronic…
Read more

Study: Short-Term Increase in Inhaled Steroids Won’t Prevent Children’s Asthma Flare-Ups 

Researchers have found that temporarily increasing the dosage of inhaled steroids when asthma symptoms begin to worsen does not effectively prevent severe flare-ups and may be associated with slowing a child’s growth, challenging a common medical practice involving children with mild-to-moderate asthma.…
Read more

OxyContin Maker Stops Promoting Opioids, Cuts Sales Staff

OxyContin maker Purdue Pharma LP says it has cut its sales force in half and will stop promoting opioids to physicians following widespread criticism of the ways that drug makers market addictive painkillers, Reuters reported. The drug maker is informing doctors that its sales representatives will no…
Read more

Health, Medical Groups Sue FDA Over E-Cigarette Rule Delay

Seven public health and medical groups have filed a lawsuit challenging an FDA decision that they said would allow e-cigarettes to remain on the market for years without regulatory review, Reuters reports. The lawsuit, filed in federal court in Greenbelt, Maryland, argued the FDA in August improperly…
Read more

Pages

  • « first
  • ‹ previous
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • next ›
  • last »
Facebook Twitter LinkedIn RSS Feed
  • Contact Us
  • Our History
  • Terms & Conditions of Use Agreement
  • Address and Subscription Changes
  • 2018 Editorial Calendar
  • 2018 Space and Material Due Dates
  • BPA Statement
  • Submitting Original Research
  • Submitting Viewpoints
  • Site Map
  • Contact Webmaster
  • P&T Community
© 2018 MediMedia, an ICON plc company. All rights reserved.